Simcere climbs on license deal with Vigonvita

Simcere Pharmaceutical

04/12/2025 04:41

** Simcere Pharmaceutical Group 2096.HK climbs 3.7% to HK$13.59; set for biggest one-day pct gain since November 13

** Stock set to snap two straight sessions of fall

** Generic drug producer obtains exclusive license rights to Vigonvita Life Science's 2630.HK Deuterated Remdesivir Hydrobromide in the Greater China region

** Drug used to treat respiratory syncytial virus, human metapneumovirus (HMPV) infection

** Co says collaboration will strengthen group's product deployment in anti-infection area

** Vigonvita's stock slips 2.5% to HK$74.1

** YTD, Simcere shares up 90%; Vigonvita's stock surges 236.8% since listing in Hong Kong on November 6

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))